Abstract:As a key component in combination therapy for acquired immunodeficiency syndrome (AIDS), non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been proven to be an essential way in stopping HIV-1 replication. In the present work, in silico studies were conducted on a series of 119 NNRTIs, including 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives by using the comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), docking simulations and molecular dynamics (MD). The statistical results of the optimal model, the ligand-based CoMSIA one (Q 2 = 0.48, R ncv 2 =0.847, R pre 2 = 0.745) validates its satisfactory predictive capacity both internally and externally. The contour maps, docking and MD results correlate well with each other, drawing conclusions as follows: 1) Compounds with bulky substituents in position-6 of ring A, hydrophobic groups around position- 1, 2, 6 are preferable to the biological activities; 2) Two hydrogen bonds between RT inhibitor and the Tyr 318, Lys 101 residues, respectively, and a π-π bond between the inhibitor and Trp 188 are formed and crucial to the orientation of the active conformation of the molecules; 3) The binding pocket is essentially hydrophobic, which are determined by residues such as Trp 229, Tyr 318, Val 179, Tyr 188 and Val 108, and hydrophobic substituents may bring an improvement to the biological activity; 4) DABO and HEPT derivatives have different structures but take a similar mechanism to inhibit RT. The potency difference between two isomers in HEPTs can be explained by the distinct locations of the 6-naphthylmethyl substituent and the reasons are explained in details. All these results could be employed to alter the structural scaffold in order to develop new HIV-1 RT inhibitors that have an improved biological property. To the best of our knowledge, this is the first report on 3D-QSAR modeling of this series of HEPT and DABO NNRTs. The QSAR model and the information derived, we hope, will be of great help in presenting clear guidelines and accurate activity predictions for newly designed HIV-1 reverse transcriptase (RT) inhibitor.

Theoretical Study on Anti-mutant HIV-1 Virus Activity of Diaryltriazine Analogs

Drug Resistant Mechanism of Diaryltriazine Analog Inhibitors of HIV‐1 Reverse Transcriptase Using Molecular Dynamics Simulation and 3D‐QSAR

Revealing The Drug-Resistant Mechanism For Diarylpyrimidine Analogue Inhibitors Of Hiv-1 Reverse Transcriptase

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Docking, Molecular Dynamics and Quantitative Structure-Activity Relationship Studies for HEPTs and DABOs As HIV-1 Reverse Transcriptase Inhibitors

Molecular Docking and 3D-QSAR Research of Diaryltriazines Derivatives as HIV-1 Reverse Transcriptase Inhibitors

QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains.

Identification of Novel Diarylpyrimidines As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region

3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation of a Novel Thieno[3,4-D]pyrimidine Inhibitor Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

3D-QSAR for HIV-1 reverse transcriptase inhibitors

Novel Diaryltriazines with A Picolinonitrile Moiety As Potent Hiv-1 Rt Inhibitors: A Patent Evaluation of Wo2016059647(A2)

Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity Against K103N and E138K Mutants and Pharmacokinetic Profiles

Improving the Positional Adaptability: Structure-Based Design of Biphenyl-Substituted Diaryltriazines As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Computational Studies and Drug Design for HIV-1 Reverse Transcriptase Inhibitors of 3′, 4′-Di-o-(s)-camphanoyl-(+)-cis-khellactone (DCK) Analogs.

Diarylaniline Derivatives As a Distinct Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives As Potent HIV-1 NNRTIs.

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.

Physicochemical Property-Driven Optimization of Diarylaniline Compounds As Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Targeting the Hydrophobic Channel of NNIBP: Discovery of Novel 1,2,3-Triazole-derived Diarylpyrimidines As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and K103N Mutant Virus

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation